Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Blue Sky MD vs VyrarX

Blue Sky MD
Graded #157

Lower grade

vs+0.8999999999999915
VyrarX
Graded #145

Higher grade

The verdict

VyrarX takes it — 68.6/100 to 67.7/100, but only just.

VyrarX grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. VyrarX is a LegitScript-certified telehealth platform offering compounded semaglutide (from $179/month) and compounded tirzepatide (from $329/month) via weekly injection, prescribed by licensed US physicians. Blue Sky MD is close behind and may still be the better fit — see the factor split below.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueBlue Sky MD +4
65
61
Dose & formulationEven
64
64
Clinical oversightBlue Sky MD +3
87
84
Labs & monitoringVyrarX +10
62
72
FulfillmentVyrarX +8
63
71
Contract termsEven
55
55
Blue Sky MD · left barVyrarX · right bar

The numbers

MetricBlue Sky MDVyrarX
WeighScore67.7/10068.6/100
GradeCC
Scorecard rank#157#145
Semaglutide$160/mo (starting dose, compounded)$179/mo (starting dose, compounded)
Tirzepatide$240/mo (starting dose, compounded)$329/mo (starting dose, compounded)
Coverage1 stateCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
Blue Sky MD

Graded #157 · C

Strengths

  • LegitScript certified and physician-led since 2008; one of the most established GLP-1 practices in the Southeast
  • Compounded semaglutide from $40/week (~$160/month) and tirzepatide from $60/week (~$240/month) — well below brand-name cost
  • Comprehensive program includes 1-on-1 wellness coaching, nutrition plans, hormone analysis, and a proprietary mobile app
  • Medication shipped directly to patients’ homes within 3–5 business days; telehealth visits available
  • Insurance accepted in many cases; affordable self-pay options for uninsured patients

Where it loses points

  • Geographic reach unclear — physical clinics in NC only; telehealth states beyond NC unconfirmed despite 'from virtually anywhere' claim
  • Pricing quoted per-week ($40 sema / $60 tirz) rather than per-month; higher-dose pricing not disclosed
  • Must enroll in full medical weight-loss program to access GLP-1 medications — medication-only Rx not offered
  • No explicit lab testing protocol published; online FAQ does not confirm labs are included
  • Small regional provider vs. national platforms; limited provider footprint outside North Carolina
VyrarX

Graded #145 · C

Strengths

  • LegitScript certified with active seal (ID 51177727)
  • Semaglutide starting at $179/month with free shipping included
  • 1:1 direct provider messaging and personalized titration plan in every plan
  • Nutrition coaching included with the weight-loss program
  • Provider review completed within 24 hours; no insurance required

Where it loses points

  • Tirzepatide at $329/month starting is at the high end of the compounded market
  • Compounding pharmacy not named on any public page
  • No physician names or clinical leadership disclosed publicly
  • Only 47 states covered — the 3 excluded states are not named on the site
  • Labs not included in the weight-loss plan

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard